Chris Efessiou is a significant addition to our advisory team to serve clients focused on accelerating their next phases of growth
WASHINGTON, D.C (PRWEB) January 30, 2018
Expert advisory firm Newport Board Group, LLC continues to expand nationally, announcing today the admission of Christos Efessiou, a healthcare, biotech and pharma senior executive and subject matter expert as a member of the LLC and Partner in its Mid-Atlantic practice.
Mr. Efessiou brings more than three decades of relevant experience to Newport's expert network, advising emerging growth and lower middle-market companies on a wide range of strategic growth, research, product development, marketing, commercialization and transactional topics. Chris has a proven record of driving results and enhancing enterprise value with his deep experience as a business builder, advisor and CEO for both commercial enterprises and non-profit clients and as a consultant to VC and PE-funded healthcare companies.
"Chris Efessiou is a significant addition to our advisory team to serve clients focused on accelerating their next phases of growth," said Tony Cord, Managing Director of Newport Board Group’s Mid-Atlantic practice. “We are confident Chris’ senior level, hands-on expertise, outstanding reputation and international connections will be invaluable to emerging growth company leaders tackling the unique complex challenges of biotech and pharma innovators. He is one of a growing number of Newport partners experienced in building public private partnerships, which are driving innovation across the economy and are especially important in the Washington, D.C. area.” Mr. Efessiou will continue to operate his advisory consultancy, SRxA Strategic Pharmaceutical Advisors, LLC. At Newport, Efessiou’s focus will be advising executive teams, boards of directors and investor groups on corporate and business strategy, and help drive operational improvements and access to resources to support growth. His specific areas of focus include high-potential funded start-ups, emerging growth companies with 20-100 employees, and lower mid-market companies with over 100 employees and generating revenues. Chris will be available to serve clients locally, regionally, nationally and internationally.
“I am very pleased and excited to join the Newport Board Group’s network of seasoned professionals and provide present and future clients with actionable guidance, out-of-the-box thinking and on-point results, and help them pilot their organizations from start-up to commercial success,” said Chris Efessiou.
Prior to joining Newport, and leading SRxA, he concurrently served as an Advisor and Venture Partner at Alergos Pharmaceuticals and Strategic Pharmaceuticals Company, and founder of Strategic Implications International, which was later acquired by BLPG and Cardinal Health. He is a current board member of Saving Promise, an advisory board member of the American Patient Rights Association and a founding mentor at The Maryland Tech Council Venture Mentoring Service.
Mr. Efessiou is a member of several industry associations, including the U.S. Chamber of Commerce and VA-Bio. He and his family reside in Vienna, Virginia. Newport Board Group is a unique national professional services firm of CEOs, senior executives and board members who collaborate to serve emerging growth and entrepreneurial middle market companies and the private equity firms that invest in them. By working together in local practices in major cities and across the country, Newport partners create solutions to help clients improve their performance and valuation and become more transaction-ready.
For an interview or photograph, please contact Mark Rosenman, Chief Knowledge Officer at mark.rosenman(at)newportboardgroup(dot)com or 973.509.3838